focus -WSS

focus

author：comprehensive 2025-09-27 21:54:29 - browse：26

Today, if you want to know what scary family health secrets lay buried in your DNA or get screened for a lurking cancer, you have a lot of options. Laboratories have developed more than 75,000 genetic tests, with about 10 new ones entering the market daily. By the end of 2019, more than 26 million Americans had had their DNA decoded to some degree or another. Since then, that number has surely grown.

But this testing frenzy would have been inconceivable just 10 years ago. In part, that’s because the technology back then was so expensive. More importantly, until 2013, it was common practice for gene-hunting academics and companies to lock up their discoveries with DNA patents, effectively carving up the human genome into mini-monopolies. That year, the U.S. Supreme Court threw a bomb into the biotech world when it took up a landmark case that pitted cancer survivors and the American Civil Liberties Union against a diagnostics company called Myriad Genetics, which had obtained exclusive patents on the cancer-causing BRCA genes and made billions of dollars selling tests for them.

A new book called “The Genome Defense,” written by University of Utah science and technology law expert Jorge Contreras and being published Oct. 26, provides a front-row seat to the courtroom drama that would upend three decades of federal intellectual property law and chart a new course toward balancing corporate profits with the rights of all people to the information written into their DNA.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Kellogg’s is going to war over Mexico’s nutrition label rules

WSS

Study: Spinal cord stimulation helps patients with paralysis walk again

Intellia plays down concerns on accidental germline transmission

Kellogg’s is going to war over Mexico’s nutrition label rules

Meadows told special counsel he could not recall Trump ever declassifying Mar

Fauci’s Covid grilling leads GOP to weigh foreign research rules

DeSantis can now import cheaper drugs. But will Biden get credit?

focus

focus

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

The high cost of giving birth even with insurance

Caregivers of transplant patients call for more support, training

Continuity nursing helped my family in our darkest PICU moments

The SUPPORT Act is critical to fighting the opioid crisis

Guidelines to prevent youth baseball injuries need more muscle

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

Sports medicine is finally prioritizing gender equality

Trump to be booked at notorious Fulton County Jail at center of DOJ probe

Duchenne breakthrough therapy leaves behind pioneering families

Designating disabled people as health disparity population is crucial

hotspot

Study: Spinal cord stimulation helps patients with paralysis walk again

Biotech reporter’s notebook: A sunnier mood at JPM 2024

DeSantis wants to import drugs. Biden’s FDA blasted his plan

Designating disabled people as health disparity population is crucial

Biotech reporter’s notebook: A sunnier mood at JPM 2024

As JPM 2024 winds down, some health tech firms project optimism

hotspot

explore

explore

focus